Results 141 to 150 of about 11,301 (165)

PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention. [PDF]

Lipids Health Dis
Marco-Benedí V, Sánchez-Hernández RM, Díaz JL, Jarauta E, Suárez-Tembra M, Pintó X, Morillas C, Plana N, Pedro-Botet J, Civeira F.   +9 more
europepmc   +1 more source

Lower body mass index is associated with the achievement of target LDL in patients using PCSK9 inhibitors in Taiwan. [PDF]

Eur J Med Res
Tu KC, Chang WT, Lin HW, Lin PL, Wu YW, Lin CF, Yeh HI, Charng MJ, Huang PH, Lin TH, Lin WW, Hsieh IC, Kuo FY, Chen CP, Lin SH, Li YH.   +15 more
europepmc   +1 more source

Treatment with PCSK9 inhibitors influences microRNAs expression and changes of arterial wall properties: a randomized controlled trial. [PDF]

Eur J Med Res
Rehberger Likozar A, Levstek T, Karun T, Trebušak Podkrajšek K, Zupan J, Šebeštjen M.   +5 more
europepmc   +1 more source

Genetic Variants, Bioactive Compounds, and PCSK9 Inhibitors in Hyper-LDL-Cholesterolemia: A GWAS and In Silico Study on Cardiovascular Disease Risk. [PDF]

Nutrients
Liu M, Zhou J, Park S.
europepmc   +1 more source

PCSK9 inhibitors in real life-Cardiometabolic risk management in dyslipidemic patients in Vienna. [PDF]

Wien Klin Wochenschr
Ferch M, Sert C, Fellinger P, Kautzky-Willer A, Winhofer-Stöckl Y.   +4 more
europepmc   +1 more source

The therapeutic effect of PCSK9 inhibitors on dyslipidemia: one-year follow up. [PDF]

Eur J Transl Myol
Moshkani Farahani M, Nasiri A, Salari M, Shamsedini A.   +3 more
europepmc   +1 more source

Statins Versus Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Primary Cardiovascular Prevention in High-Risk Patients: A Systematic Review. [PDF]

Cureus
Khan S, Asif A, Omer O, Gondal MZD, Tallal H, Abbas T.   +5 more
europepmc   +1 more source

Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond. [PDF]

Am J Prev Cardiol
Safarova M, Bimal T, Soffer DE, Hirsh B, Shapiro MD, Mintz G, Cha A, Gianos E.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Oral PCSK9 Inhibitors

Current Atherosclerosis Reports
In this review, we will discuss the data from early clinical studies of MK-0616 and summarize clinical trials of other oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.The success of PCSK9 inhibition with monoclonal antibody injections has fueled the development of additional therapies targeting PCSK9, including oral formulations ...
Anandita, Agarwala, Ramsha, Asim, Christie M, Ballantyne   +2 more
openaire   +3 more sources